These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 38082142)

  • 1. New Therapies on the Horizon for Primary Biliary Cholangitis.
    Tanaka A
    Drugs; 2024 Jan; 84(1):1-15. PubMed ID: 38082142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Wong LL; Hegade VS; Jones DEJ
    Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and Treatment of Primary Biliary Cholangitis].
    Kim KA
    Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.
    Ronca V; Carbone M; Bernuzzi F; Malinverno F; Mousa HS; Gershwin ME; Invernizzi P
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1121-1131. PubMed ID: 28994348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Primary biliary cholangitis].
    Soret PA; Chazouillères O; Corpechot C
    Rev Prat; 2021 Oct; 71(8):885-891. PubMed ID: 35147347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PRIMARY BILIARY CHOLANGITIS: THERAPEUTIC APPROACH IN THE MODERN ERA].
    Abu Backer F; Abu Mouch S; Mari A
    Harefuah; 2018 Dec; 157(12):791-796. PubMed ID: 30582314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in the treatment of primary biliary cholangitis].
    Li YM; Wang QX; Ma X
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):805-809. PubMed ID: 29325272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?
    Yang Y; He X; Rojas M; Leung PSC; Gao L
    Front Immunol; 2023; 14():1184252. PubMed ID: 37325634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
    Silveira MG; Lindor KD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for the treatment of Primary Biliary Cholangitis.
    Ali AH; Tabibian JH; Carey EJ; Lindor KD
    Expert Opin Emerg Drugs; 2016; 21(1):39-56. PubMed ID: 26901615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary biliary cirrhosis: safety and benefits of established and emerging therapies.
    Tabibian JH; Lindor KD
    Expert Opin Drug Saf; 2015; 14(9):1435-44. PubMed ID: 26212223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical management of primary biliary cholangitis.
    Parés A;
    Rev Esp Enferm Dig; 2022 Jul; 114(7):410-417. PubMed ID: 34663072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Treatment Paradigms in Primary Biliary Cholangitis.
    Levy C; Manns M; Hirschfield G
    Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2076-2087. PubMed ID: 36809835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.
    Gallucci GM; Hayes CM; Boyer JL; Barbier O; Assis DN; Ghonem NS
    Cells; 2024 Aug; 13(15):. PubMed ID: 39120326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
    J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.
    Zhang H; Li S; Feng Y; Zhang Q; Xie B
    Clin Exp Med; 2023 Sep; 23(5):1741-1749. PubMed ID: 36318376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.